GP2
Pancreatic secretory granule membrane major glycoprotein GP2
Also known as: GP2_HUMAN, ZAP75
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P55259
- Gene
- GP2
- Ensembl
- ENSG00000169347
- Chromosome
- 16
- Canonical length
- 537 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
- Secretome location
- Secreted to digestive system
OverviewNCBI Gene
This gene encodes an integral membrane protein that is secreted from intracellular zymogen granules and associates with the plasma membrane via glycosylphosphatidylinositol (GPI) linkage. The encoded protein binds pathogens such as enterobacteria, thereby playing an important role in the innate immune response. The C-terminus of this protein is related to the C-terminus of the protein encoded by the neighboring gene, uromodulin (UMOD). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2015]
Canonical amino-acid sequenceUniProt
537 residues, UniProt reviewed canonical sequence.
>P55259|GP2
1 MPHLMERMVG SGLLWLALVS CILTQASAVQ RGYGNPIEAS SYGLDLDCGA PGTPEAHVCF
61 DPCQNYTLLD EPFRSTENSA GSQGCDKNMS GWYRFVGEGG VRMSETCVQV HRCQTDAPMW
121 LNGTHPALGD GITNHTACAH WSGNCCFWKT EVLVKACPGG YHVYRLEGTP WCNLRYCTVP
181 RDPSTVEDKC EKACRPEEEC LALNSTWGCF CRQDLNSSDV HSLQPQLDCG PREIKVKVDK
241 CLLGGLGLGE EVIAYLRDPN CSSILQTEER NWVSVTSPVQ ASACRNILER NQTHAIYKNT
301 LSLVNDFIIR DTILNINFQC AYPLDMKVSL QAALQPIVSS LNVSVDGNGE FIVRMALFQD
361 QNYTNPYEGD AVELSVESVL YVGAILEQGD TSRFNLVLRN CYATPTEDKA DLVKYFIIRN
421 SCSNQRDSTI HVEENGQSSE SRFSVQMFMF AGHYDLVFLH CEIHLCDSLN EQCQPSCSRS
481 QVRSEVPAID LARVLDLGPI TRRGAQSPGV MNGTPSTAGF LVAWPMVLLT VLLAWLFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 33,354 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 33,354 nTPM
- duodenum: 34 nTPM
- prostate: 33 nTPM
- kidney: 28 nTPM
- stomach: 26 nTPM
- gallbladder: 18 nTPM
Single-cell type
- pancreatic acinar cells: 20,522 nCPM
- prostatic glandular cells: 526 nCPM
- pancreatic duct cells: 199 nCPM
- loop of henle epithelial cells: 160 nCPM
- paneth cells: 54 nCPM
- cholangiocytes: 48 nCPM
Immune cell
- basophil: 0.3 nTPM
- neutrophil: 0.3 nTPM
- naive B-cell: 0.2 nTPM
- plasmacytoid DC: 0.2 nTPM
- classical monocyte: 0.1 nTPM
- eosinophil: 0.1 nTPM
Brain region
- midbrain: 2.1 nTPM
- cerebellum: 2 nTPM
- choroid plexus: 1.6 nTPM
- cerebral cortex: 1.5 nTPM
- white matter: 1.5 nTPM
- medulla oblongata: 1.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GP2.
Disease | AutoantibodyPubMed
Conditions in which antibodies against GP2 are reported. Each links to that disease's full target list.
Showing 2 of 3 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for GP2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
31 publications
- Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
2009 · Gut · RCR 2.8 · 112 citations - Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
2017 · Gut · RCR 2.3 · 63 citations - Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
2021 · Aliment Pharmacol Ther · RCR 2.3 · 33 citations - Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
2013 · J Crohns Colitis · RCR 1.7 · 56 citations - Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
2012 · BMC Gastroenterol · RCR 1.5 · 46 citations
Show 20 more of 31 total
- Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
2011 · Clin Chim Acta · RCR 1.5 · 54 citations - Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
2015 · J Crohns Colitis · RCR 1.5 · 41 citations - Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
2011 · Autoimmun Rev · RCR 1.5 · 50 citations - Glycoprotein 2 antibodies in Crohn's disease.
2013 · Adv Clin Chem · RCR 1.2 · 34 citations - Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases.
2012 · Gut · RCR 1.2 · 36 citations - Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
2012 · Clin Dev Immunol · RCR 1.2 · 34 citations - Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
2016 · Inflamm Bowel Dis · RCR 1.1 · 26 citations - Glycoprotein 2 as a gut gate keeper for mucosal equilibrium between inflammation and immunity.
2024 · Semin Immunopathol · RCR 1 · 6 citations - Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges.
2014 · Clin Chem Lab Med · RCR 1 · 33 citations - Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
2016 · Inflamm Bowel Dis · RCR 1 · 30 citations - Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
2018 · Sci Rep · RCR 0.9 · 24 citations - Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
2016 · Clin Chem Lab Med · RCR 0.9 · 23 citations - Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
2013 · J Crohns Colitis · RCR 0.8 · 24 citations - The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.
2013 · Gastroenterol Res Pract · RCR 0.8 · 24 citations - Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap.
2012 · Clin Chim Acta · RCR 0.8 · 22 citations - Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
2015 · Clin Chem Lab Med · RCR 0.5 · 11 citations - Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.
2015 · PLoS One · RCR 0.5 · 11 citations - Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
2017 · Inflamm Bowel Dis · RCR 0.4 · 11 citations - Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
2015 · Medicine (Baltimore) · RCR 0.3 · 7 citations - Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
2018 · Aliment Pharmacol Ther · RCR 0.2 · 5 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.42
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.7
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- innate immune response
- neutrophil migration
- antigen transcytosis by M cells in mucosal-associated lymphoid tissue
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GP2 as an antibody target. Whether an autoantibody or antibody against GP2 could matter depends on whether native GP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GP2 is annotated at the cell surface, where native GP2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...